“…cART lowers T cell activation, raises CD4 counts, decreases HIV VL and thus interferes significantly with other factors associated with HIV disease progression (Autran et al 1997, Carcelain et al 2001, Lederman 2001). Since the vast majority of subjects in the study of Baggio-Zappia et al (2011) were effectively treated by cART, it is not surprising that GBV-C did not have an observed effect on the clinical variables studied (CD4, HIV VL etc. ).…”